$VSTM Company News Stocks to watch Thursday: Gre
Post# of 89085
Posted On: 01/09/2014 2:01:14 PM
$VSTM Company News
Stocks to watch Thursday: Green Mountain, Merck 6:55 a.m. Feb. 2, 2012 - MarketWatch
A busy IPO year as Facebook buzz builds 4:46 p.m. Jan. 30, 2012 - Benjamin Pimentel
Verastem climbs in early post-IPO trading 10:55 a.m. Jan. 27, 2012 - MarketWatch.com
Verastem Initiates Phase 1 Trial of Dual mTOR/PI3K Inhibitor 6:16 a.m. Dec. 10, 2013 - benzinga.com
Verastem (VSTM) in Focus: Stock Rises by 7.3% - Tale of the Tape 9:11 a.m. Dec. 6, 2013 - Zacks.com
Investments On Biotech's Cutting Edge: Joseph Pantginis 4:41 p.m. Nov. 18, 2013 - Seeking Alpha
10-Q: VERASTEM, INC. 7:21 a.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Should You Follow Insiders On These 3 Stocks? 6:58 p.m. Nov. 4, 2013 - Seeking Alpha
Killing Cancer Stem Cells: The Final Battle? 2:48 p.m. Oct. 27, 2013 - Seeking Alpha
Novel Therapies and Defeating Multi-Drug Resistance Key in Success of Cancer Drug Companies 12:01 p.m. Oct. 23, 2013 - Wall St. Cheat Sheet
Will Galena's Initiatives Translate Into Positive Returns? 4:09 p.m. Sept. 28, 2013 - Seeking Alpha
Verastem Begins Phase 2 Trial of Defatinib in Lunc Cancer 7:37 a.m. Sept. 26, 2013 - benzinga.com
Verastem Initiates Defactinib Trial in Japan 5:04 a.m. Sept. 24, 2013 - benzinga.com
Verastem: An Attractive Long-Term Investment In The Cancer Stem Cell Space 5:12 a.m. Sept. 17, 2013 - Seeking Alpha
Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter 5:01 a.m. Aug. 15, 2013 - benzinga.com
10-Q: VERASTEM, INC. 8:19 a.m. Aug. 13, 2013 - Edgar Online - (EDG = 10Q, 10K)
6 Reasons ImmunoCellular Therapeutics Is One Of The Best Risk Vs. Rewards In The Market 9:00 a.m. Aug. 7, 2013 - Seeking Alpha
6 Oncology-Focused Biotech Growth Engines: Mara Goldstein 5:01 p.m. Aug. 2, 2013 - Seeking Alpha
UPDATE: Jefferies Initiates Verastem at Buy on Cancer Research Potential 7:23 a.m. July 29, 2013 - benzinga.com
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma 5:08 a.m. July 24, 2013 - benzinga.com
Verastem Drug Achieves a Complete Response in Platinum-Resistant Ovarian Cancer 5:16 a.m. July 23, 2013 - benzinga.com
Verastem Announces Pricing of Public Offering of Common Stock At $15 7:25 a.m. July 17, 2013 - benzinga.com
Verastem Announces Proposed Public Offering of Common Stock 2:09 p.m. July 16, 2013 - benzinga.com
Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research Report on Cantel, Chimerix, Verastem, Amedisys, and Ensign Group 8:00 a.m. Dec. 25, 2013 - PR Newswire
Verastem Announces Addition to the NASDAQ Biotechnology Index 7:00 a.m. Dec. 19, 2013 - BusinessWire
Annual Changes to the NASDAQ Biotechnology Index 8:05 a.m. Dec. 16, 2013 - GlobeNewswire
Verastem Initiates Clinical Trial of Dual mTOR/PI3K Inhibitor 7:00 a.m. Dec. 10, 2013 - BusinessWire
Verastem to Present at Upcoming Conferences 7:00 a.m. Nov. 26, 2013 - BusinessWire
Verastem Reports Third Quarter 2013 Financial and Corporate Results 7:00 a.m. Nov. 12, 2013 - BusinessWire
Verastem Names Jose Baselga, M.D., Ph.D. as Senior Medical Advisor 6:00 a.m. Oct. 31, 2013 - BusinessWire
Verastem Announces Presentations at the 2013 World Conference on Lung Cancer 6:00 a.m. Oct. 24, 2013 - BusinessWire
Verastem Announces Presentation of VS-6063 Clinical and Preclinical Study Results at the 2013 AACR-NCI-EORTC International Conference 6:00 a.m. Oct. 21, 2013 - BusinessWire
Verastem Executives Featured at Boston-Area Biotechnology Events 6:00 a.m. Oct. 15, 2013 - BusinessWire
Verastem Announces Presentations at the 2013 AACR-NCI-EORTC International Conference 6:00 a.m. Oct. 10, 2013 - BusinessWire
Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer 8:36 a.m. Sept. 26, 2013 - BusinessWire
Verastem Initiates Trial of Defactinib in Japan 6:00 a.m. Sept. 24, 2013 - BusinessWire
Verastem Reports on Ongoing Trials at Cancer Advance at Harvard Medical School 3:00 p.m. Sept. 19, 2013 - BusinessWire
Verastem to Present at Upcoming Scientific and Investor Conferences 6:00 a.m. Sept. 18, 2013 - BusinessWire
Veristat to Assist on Adaptive Enrichment Trial for Verastem's Defactinib in Mesothelioma 4:12 p.m. Sept. 10, 2013 - BusinessWire
Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma 6:00 a.m. Sept. 10, 2013 - BusinessWire
Verastem to Present at Upcoming Conferences 6:00 a.m. Sept. 3, 2013 - BusinessWire
Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter 6:00 a.m. Aug. 15, 2013 - BusinessWire
Verastem Reports Second Quarter 2013 Financial and Corporate Results 6:00 a.m. Aug. 13, 2013 - BusinessWire
Stocks to watch Thursday: Green Mountain, Merck 6:55 a.m. Feb. 2, 2012 - MarketWatch
A busy IPO year as Facebook buzz builds 4:46 p.m. Jan. 30, 2012 - Benjamin Pimentel
Verastem climbs in early post-IPO trading 10:55 a.m. Jan. 27, 2012 - MarketWatch.com
Verastem Initiates Phase 1 Trial of Dual mTOR/PI3K Inhibitor 6:16 a.m. Dec. 10, 2013 - benzinga.com
Verastem (VSTM) in Focus: Stock Rises by 7.3% - Tale of the Tape 9:11 a.m. Dec. 6, 2013 - Zacks.com
Investments On Biotech's Cutting Edge: Joseph Pantginis 4:41 p.m. Nov. 18, 2013 - Seeking Alpha
10-Q: VERASTEM, INC. 7:21 a.m. Nov. 12, 2013 - Edgar Online - (EDG = 10Q, 10K)
Should You Follow Insiders On These 3 Stocks? 6:58 p.m. Nov. 4, 2013 - Seeking Alpha
Killing Cancer Stem Cells: The Final Battle? 2:48 p.m. Oct. 27, 2013 - Seeking Alpha
Novel Therapies and Defeating Multi-Drug Resistance Key in Success of Cancer Drug Companies 12:01 p.m. Oct. 23, 2013 - Wall St. Cheat Sheet
Will Galena's Initiatives Translate Into Positive Returns? 4:09 p.m. Sept. 28, 2013 - Seeking Alpha
Verastem Begins Phase 2 Trial of Defatinib in Lunc Cancer 7:37 a.m. Sept. 26, 2013 - benzinga.com
Verastem Initiates Defactinib Trial in Japan 5:04 a.m. Sept. 24, 2013 - benzinga.com
Verastem: An Attractive Long-Term Investment In The Cancer Stem Cell Space 5:12 a.m. Sept. 17, 2013 - Seeking Alpha
Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter 5:01 a.m. Aug. 15, 2013 - benzinga.com
10-Q: VERASTEM, INC. 8:19 a.m. Aug. 13, 2013 - Edgar Online - (EDG = 10Q, 10K)
6 Reasons ImmunoCellular Therapeutics Is One Of The Best Risk Vs. Rewards In The Market 9:00 a.m. Aug. 7, 2013 - Seeking Alpha
6 Oncology-Focused Biotech Growth Engines: Mara Goldstein 5:01 p.m. Aug. 2, 2013 - Seeking Alpha
UPDATE: Jefferies Initiates Verastem at Buy on Cancer Research Potential 7:23 a.m. July 29, 2013 - benzinga.com
Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma 5:08 a.m. July 24, 2013 - benzinga.com
Verastem Drug Achieves a Complete Response in Platinum-Resistant Ovarian Cancer 5:16 a.m. July 23, 2013 - benzinga.com
Verastem Announces Pricing of Public Offering of Common Stock At $15 7:25 a.m. July 17, 2013 - benzinga.com
Verastem Announces Proposed Public Offering of Common Stock 2:09 p.m. July 16, 2013 - benzinga.com
Financial Results, Conference Presentation Schedule, Clinical Trial Initiation, Recognition, and Dividend Payment - Research Report on Cantel, Chimerix, Verastem, Amedisys, and Ensign Group 8:00 a.m. Dec. 25, 2013 - PR Newswire
Verastem Announces Addition to the NASDAQ Biotechnology Index 7:00 a.m. Dec. 19, 2013 - BusinessWire
Annual Changes to the NASDAQ Biotechnology Index 8:05 a.m. Dec. 16, 2013 - GlobeNewswire
Verastem Initiates Clinical Trial of Dual mTOR/PI3K Inhibitor 7:00 a.m. Dec. 10, 2013 - BusinessWire
Verastem to Present at Upcoming Conferences 7:00 a.m. Nov. 26, 2013 - BusinessWire
Verastem Reports Third Quarter 2013 Financial and Corporate Results 7:00 a.m. Nov. 12, 2013 - BusinessWire
Verastem Names Jose Baselga, M.D., Ph.D. as Senior Medical Advisor 6:00 a.m. Oct. 31, 2013 - BusinessWire
Verastem Announces Presentations at the 2013 World Conference on Lung Cancer 6:00 a.m. Oct. 24, 2013 - BusinessWire
Verastem Announces Presentation of VS-6063 Clinical and Preclinical Study Results at the 2013 AACR-NCI-EORTC International Conference 6:00 a.m. Oct. 21, 2013 - BusinessWire
Verastem Executives Featured at Boston-Area Biotechnology Events 6:00 a.m. Oct. 15, 2013 - BusinessWire
Verastem Announces Presentations at the 2013 AACR-NCI-EORTC International Conference 6:00 a.m. Oct. 10, 2013 - BusinessWire
Verastem Initiates Phase 2 Trial of Defactinib in Lung Cancer 8:36 a.m. Sept. 26, 2013 - BusinessWire
Verastem Initiates Trial of Defactinib in Japan 6:00 a.m. Sept. 24, 2013 - BusinessWire
Verastem Reports on Ongoing Trials at Cancer Advance at Harvard Medical School 3:00 p.m. Sept. 19, 2013 - BusinessWire
Verastem to Present at Upcoming Scientific and Investor Conferences 6:00 a.m. Sept. 18, 2013 - BusinessWire
Veristat to Assist on Adaptive Enrichment Trial for Verastem's Defactinib in Mesothelioma 4:12 p.m. Sept. 10, 2013 - BusinessWire
Verastem Initiates COMMAND: A Registration-Directed Trial of Defactinib in Patients with Mesothelioma 6:00 a.m. Sept. 10, 2013 - BusinessWire
Verastem to Present at Upcoming Conferences 6:00 a.m. Sept. 3, 2013 - BusinessWire
Verastem Issued U.S. Patent Covering VS-4718 Composition of Matter 6:00 a.m. Aug. 15, 2013 - BusinessWire
Verastem Reports Second Quarter 2013 Financial and Corporate Results 6:00 a.m. Aug. 13, 2013 - BusinessWire
(0)
(0)Scroll down for more posts ▼